Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy
- PMID: 18696232
- DOI: 10.1007/s10585-008-9200-4
Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy
Abstract
NSCLC cells with a mesenchymal phenotype have shown a marked reduction in sensitivity to EGFR inhibitors, though the molecular rationale has remained obscure. Here we find that in mesenchymal-like tumor cells both tyrosine phosphorylation of EGFR, ErbB2, and ErbB3 signaling networks and expression of EGFR family ligands were decreased. While chronic activation of EGFR can promote an EMT-like transition, once having occurred EGFR family signaling was attenuated. We investigated the mechanisms by which mesenchymal-like cells bypass EGFR signaling and acquire alternative routes of proliferative and survival signaling. Mesenchymal-like NSCLC cells exhibit aberrant PDGFR and FGFR expression and autocrine signaling through these receptors can activate the MEK-ERK and PI3K pathways. Selective pharmacological inhibition of PDGFR or FGFR receptor tyrosine kinases reduced cell proliferation in mesenchymal-like but not epithelial NSCLC cell lines. A metastable, reversible EMT-like transition in the NSCLC line H358 was achieved by exogenous TGFbeta, which served as a model EMT system. The H358/TGFbeta cells showed many of the attributes of established mesenchymal-like NSCLC cells including a loss of cell-cell junctions, a loss of EGF-family ligand expression, a loss of ErbB3 expression, increased EGFR-independent Mek-Erk pathway activation and reduced sensitivity to EGFR inhibition. Notably an EMT-dependent acquisition of PDGFR, FGFR and TGFbeta receptors in H358/TGFbeta cells was also observed. In H358/TGFbeta cells both PDGFR and FGFR showed functional ligand stimulation of their intrinsic tyrosine kinase activities. The findings of kinase switching and acquired PDGFR and FGFR signaling suggest investigation of new inhibitor combinations to target NSCLC metastases.
Similar articles
-
LMNA Reduced Acquired Resistance to Erlotinib in NSCLC by Reversing the Epithelial-Mesenchymal Transition via the FGFR/MAPK/c-fos Signaling Pathway.Int J Mol Sci. 2022 Oct 31;23(21):13237. doi: 10.3390/ijms232113237. Int J Mol Sci. 2022. PMID: 36362025 Free PMC article.
-
Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.Cancer Sci. 2018 Oct;109(10):3183-3196. doi: 10.1111/cas.13763. Epub 2018 Sep 14. Cancer Sci. 2018. PMID: 30098066 Free PMC article.
-
ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.PLoS One. 2016 Jan 20;11(1):e0147344. doi: 10.1371/journal.pone.0147344. eCollection 2016. PLoS One. 2016. PMID: 26789630 Free PMC article.
-
The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer.Drug Resist Updat. 2009 Aug-Oct;12(4-5):95-102. doi: 10.1016/j.drup.2009.05.001. Epub 2009 Jun 4. Drug Resist Updat. 2009. PMID: 19501013 Free PMC article. Review.
-
[Aberrant Activation Mechanism of TGF-β Signaling in Epithelial-mesenchymal Transition].Yakugaku Zasshi. 2021;141(11):1229-1234. doi: 10.1248/yakushi.21-00143. Yakugaku Zasshi. 2021. PMID: 34719542 Review. Japanese.
Cited by
-
Epidermal Growth Factor Receptor Targeting in Colorectal Carcinoma: Antibodies and Patient-Derived Organoids as a Smart Model to Study Therapy Resistance.Int J Mol Sci. 2024 Jun 28;25(13):7131. doi: 10.3390/ijms25137131. Int J Mol Sci. 2024. PMID: 39000238 Free PMC article. Review.
-
Eribulin sensitizes oral squamous cell carcinoma cells to cetuximab via induction of mesenchymal-to-epithelial transition.Oncol Rep. 2016 Dec;36(6):3139-3144. doi: 10.3892/or.2016.5189. Epub 2016 Oct 21. Oncol Rep. 2016. PMID: 27779690 Free PMC article.
-
The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells.Sci Signal. 2013 Aug 6;6(287):ra66. doi: 10.1126/scisignal.2004155. Sci Signal. 2013. PMID: 23921085 Free PMC article.
-
Decoupling of Nrf2 Expression Promotes Mesenchymal State Maintenance in Non-Small Cell Lung Cancer.Cancers (Basel). 2019 Oct 2;11(10):1488. doi: 10.3390/cancers11101488. Cancers (Basel). 2019. PMID: 31581742 Free PMC article.
-
Transforming growth factor-β-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression.Oncogene. 2010 Dec 9;29(49):6485-98. doi: 10.1038/onc.2010.377. Epub 2010 Aug 30. Oncogene. 2010. PMID: 20802523 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous